Corbus Pharmaceuticals Holdings, Inc (CRBP)

Currency in USD
5.7800
-0.0700(-1.20%)
Closed·
5.78000.0000(0.00%)
·
Trading near 52-week Low
CRBP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.65005.9950
52 wk Range
5.650020.5600
Key Statistics
Prev. Close
5.85
Open
5.87
Day's Range
5.65-5.995
52 wk Range
5.65-20.56
Volume
706.22K
Average Volume (3m)
724.64K
1-Year Change
-60.1928%
Book Value / Share
5.52
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRBP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.0250
Upside
+488.67%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 34.0250
(+488.67% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy35.00+505.54%-MaintainSep 15, 2026
H.C. Wainwright
Buy35.00+505.54%-MaintainAug 26, 2026
Mizuho
Buy33.00+470.93%34.00MaintainAug 13, 2026
Oppenheimer
Buy48.00+730.45%52.00MaintainAug 07, 2026
Mizuho
Buy34.00+488.24%44.00MaintainJun 23, 2026

Corbus Pharmaceuticals Holdings, Inc SWOT Analysis


Promising Pipeline
Explore Corbus Pharmaceuticals' diverse portfolio, featuring potential best-in-class therapies for cancer and obesity, positioning the company for significant market impact
Financial Fortitude
Delve into Corbus's robust financial position, with $120.1 million in cash reserves providing runway for key development milestones and future growth
Market Opportunity
Learn how Corbus targets lucrative markets in oncology and obesity, with analysts projecting billion-dollar sales potential for lead candidates
Analyst Outlook
Discover the bullish sentiment among analysts, with price targets ranging from $77 to $85, reflecting confidence in Corbus's innovative approach and market potential
Read full SWOT analysis

Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
-1.81 / -1.26
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CRBP Income Statement

Compare CRBP to Peers and Sector

Metrics to compare
CRBP
Peers
Sector
Relationship
P/E Ratio
−1.1x1.6x−0.3x
PEG Ratio
0.040.030.00
Price/Book
1.1x4.7x2.6x
Price / LTM Sales
-7.0x3.0x
Upside (Analyst Target)
-109.7%58.5%
Fair Value Upside
Unlock15.1%7.1%Unlock

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.43M22.89%25.90M
Other Institutional Investors
15.71M77.11%91.90M
Public Companies & Retail Investors
0.000.00%0.00
Total
20.14M100.00%117.8M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Cormorant Global Healthcare Master Fund, LP12.12%2,344,97113,718
Cormorant Asset Management, LP12.12%2,344,97113,718

People Also Watch

7.750
CAPR
-0.39%
17.31
SRPT
-1.03%
0.154
DVLT
-3.94%
11.340
SLS
-2.49%

FAQ

What Is the Corbus Pharms (CRBP) Stock Price Today?

The Corbus Pharms stock price today is 5.7800 USD.

What Stock Exchange Does Corbus Pharms Trade On?

Corbus Pharms is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Corbus Pharms?

The stock symbol for Corbus Pharms is "CRBP."

What Is the Corbus Pharms Market Cap?

As of today, Corbus Pharms market cap is 111.2100M USD.

What Is Corbus Pharms's Earnings Per Share (TTM)?

The Corbus Pharms EPS (TTM) is -6.0889.

When Is the Next Corbus Pharms Earnings Date?

Corbus Pharms will release its next earnings report on Nov 10, 2026.

From a Technical Analysis Perspective, Is CRBP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Corbus Pharms Stock Split?

Corbus Pharms has split 1 times.

How Many Employees Does Corbus Pharms Have?

Corbus Pharms has 36 employees.

What is the current trading status of Corbus Pharms (CRBP)?

As of Oct 06, 2026, Corbus Pharms (CRBP) is trading at a price of 5.7800 USD, with a previous close of 5.8500 USD. The stock has fluctuated within a day range of 5.6500 USD to 5.9950 USD, while its 52-week range spans from 5.6500 USD to 20.5600 USD.

What Is Corbus Pharms (CRBP) Price Target According to Analysts?

The average 12-month price target for Corbus Pharms is 34.0250 USD, with a high estimate of 48 USD and a low estimate of 17.25 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +488.67% Upside potential.

What Is the CRBP Premarket Price?

CRBP's last pre-market stock price is 5.8600 USD. The pre-market share volume is 3,300.0000, and the stock has decreased by 0.0100, or 0.1700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.